cart

0

Total:

USD 0.00

Dear customer, your shopping cart is empty.
Start shopping now!

Use discount
 

Error! Coupon is not valid

Maybe you entered wrong code of coupon

Entered coupon Activated

PRODUCT CATEGORIES

View all categories

Abamune-L®

Abamune-L®
Customer rating:

4.4 out of 5(792 reviews)

5

(541)

4

(135)

3

(60)

2

(34)

1

(22)

Product Info:

Category: HIV/AIDS Medication

Brand: Abamune-L Brand

Price: per bottle

Savings:

In Stock: Yes

Other names for this medication: Abalam®, A Bec L®, Epzicom, Kivexa®

Quantity:

Subtotal: USD 236.25

Add to cart
  • General Info

    Abamune-L® is an antiviral agent used as part of anti-retroviral therapy of HIV-1 infection. Abamune-L® doesn't cure HIV-1 infection but it decreases the viral load in blood and enhances CD4 cells production to help ward off opportunistic infections. Abamune-L® is not for use in patients aged less than 18 years.

    Other names for this medication:

    Abalam®, A Bec L®, Epzicom, Kivexa®

    Similar Products:

    A Bec®, Virol®, Ziagen, Abamune®, Lamivir®, Lamivir® HBV, Epivir HBV, Tenvir®, Viread, Zidovir®, Efavir®, Stocrin, Nevimune®, Viramune, Atazor®, Reyataz, Daruvir®, Prezista, Ritomune®, Norvir, Isentress®, Zepdon®

    Active Ingredient:

    Abacavir, Lamivudine

    Description

    Abamune-L® manufacturer is Cipla. Abamune-L® active ingredients are Abacavir (ABC) and Abamune-L® is indicated with other anti-retroviral agents from different pharmacological classes and not with other nucleoside reverse transcriptase inhibitors (NRTIs).Lamivudine (3TC), which belong to a class of synthetic guanosine nucleoside reverse transcriptase inhibitors (NRTIs).

    Indications:

    Abamune-L® is indicated with other anti-retroviral agents from different pharmacological classes and not with other nucleoside reverse transcriptase inhibitors (NRTIs).

    -treatment of human immunodeficiency virus (HIV-1) infection, as part of a triple-drug regimen.

    MOA (mechanism of action):

    Abacavir is carbocyclic synthetic nucleoside analogue and Lamivudine is a synthetic nucleoside analogue. Intracellularly, Abacavir is converted by cellular enzymes to the active metabolite carbovir triphosphate (CBV-TP), an analogue of deoxyguanosine-5'-triphosphate (dGTP). Carbovir triphosphate inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its interfering with the growth of viral DNA. Intracellularly Lamivudine is phosphorylated to its active 5′-triphosphate metabolite, lamivudine triphosphate (3TC-TP). Thus, lamivudine triphosphate inhibits RT via DNA chain termination after incorporation of the nucleotide analogue. CBV-TP and 3TC-TP are weak inhibitors of cellular DNA polymerases α, β, and γ. Abacavir and Lamivudine are not active against HIV-2.

    Dosage

    Abamune-L® can be taken with or without food.

    The recommended dose is one tablet daily, in combination with other anti-retroviral agents.

    Safety and effectiveness of Abamune-L® in pediatric patients have not been established.

    Some people who take Abamune-L® may experience:

    -Lactic acidosis (a build up of lactic acid in the body), together with an enlarged liver. Symptoms are deep, rapid breathing, drowsiness, and non specific symptoms such as nausea, vomiting and stomach pain.

    -Hypersensitivity reaction, which may be life-threatening. Discontinue Abamune-L® as soon as hypersensitivity reaction is developed.

    -Liver problems, which may be life-threatening. Tell your healthcare provider immediately if you have any symptoms: dark (tea-colored) urine, yellowing of your skin or whites of your eyes, pale-colored stools, nausea, vomiting, pain or tenderness on your right side below your ribs, loss of appetite, or fatigue.

    -Immune reactivation syndrome (severe immune deficiency during combination anti-retroviral therapy (CART) may lead to arousal of opportunistic infections and cause serious clinical conditions), autoimmune disorders. If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness in hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please seek medical advice immediately.

    -Accumulation of body fat including central obesity, buffalo hump, peripheral wasting, facial wasting, breast enlargement and cushingoid appearance.

    Precautions:

    Not everyone responds to treatment with Abamune-L® in the same way. Your doctor should monitor the effectiveness of your treatment.

    HIV can be transmitted through sexual contact with HIV positive partner, blood (e.g., sharing needles, handling blood instruments, receiving blood transfusions, blood products, or organ/tissue transplants that were infected with HIV), childbirth, toiletries (razors and toothbrushes). Therefore, both HIV-positive and HIV-negative individuals are advised to have any kind of sex using a latex or polyurethane condom, avoid sharing needles or other things like toothbrushes or razors. It is important to discuss with doctor the precautions needed to avoid infecting other people as well as take precautions not to get infected.

    Prior starting Abamune-L® tablets, review medical history for prior exposure to any abacavir-containing product (including Abacavir, Abacavir/Dolutegravir/Lamivudine, and Abacavir/Lamivudine/Zidovudine) in order to avoid reintroduction in a patient with a history of allergy to Abacavir.

    Prior to initiating therapy with Abacavir, screening for the HLA-B*5701 allele is recommended as this decreases the risk of allergic reaction. The carriars of the HLA-B*5701 allele are at a higher risk of a hypersensitivity reaction to Abacavir.

    Never restart Abamune-L® or any other abacavir-containing product following allergic reaction to Abacavir, regardless of HLA-B*5701 status.

    Reintroduction of Abamune-L® or any other abacavir-containing product, even in patients who have no identified history or unrecognized symptoms of allergy to Abacavir therapy, can result in serious or fatal hypersensitivity reactions. Such reactions can occur within hours.

    Take special care if you have moderate or severe liver disease, you have ever had liver disease, including hepatitis B or C, you are seriously overweight (especially if you are a woman), you have severe kidney disease.

    Consult doctor before taking if you are taking phenytoin (for treating epilepsy), methadone (as a heroin substitute). Abacavir speeds up the removal of methadone from the body. If you are taking methadone, you will be checked for any withdrawal symptoms. Your methadone dose may need to be re-elevated.

    Women who are HIV-positive must not breastfeed because HIV infection can be passed on to the baby in breast milk.

    Missing a dose

    If you miss a dose you should take it as soon as you remember about your missing. If it is the time for the next dose you should continue your regular dosing schedule. Do not take a double dose of Abamune-L® to compensate the missed dose.

    Overdose

    If an overdose occurs and you are not feeling well, stop taking the medication immediately. You should seek emergency medical attention or contact your healthcare provider immediately.

    Storage

    Store at room temperature between 15 and 30 degrees C (59 and 86 degrees F) and away from excess moisture and heat. Throw away any unused medicine after the expiration date. Keep out of the reach of children.

  • Safety Information

    Abamune-L® is an antiviral agent used as part of anti-retroviral therapy of HIV-1 infection. Abamune-L® doesn't cure HIV-1 infection but it decreases the viral load in blood and enhances CD4 cells production to help ward off opportunistic infections. Abamune-L® is not for use in patients aged less than 18 years.

    Other names for this medication:

    Abalam®, A Bec L®, Epzicom, Kivexa®

    Similar Products:

    A Bec®, Virol®, Ziagen, Abamune®, Lamivir®, Lamivir® HBV, Epivir HBV, Tenvir®, Viread, Zidovir®, Efavir®, Stocrin, Nevimune®, Viramune, Atazor®, Reyataz, Daruvir®, Prezista, Ritomune®, Norvir, Isentress®, Zepdon®

    Active Ingredient:

    Abacavir, Lamivudine

    Side effects

    Allergy to Abamune-L® is a multi-organ clinical syndrome usually characterized by a sign or symptom in 2 or more of the following groups:

    group 1: fever

    group 2: rash

    group 3: gastrointestinal (including nausea, vomiting, diarrhea, or abdominal pain)

    group 4: constitutional (including generalized malaise, fatigue, or achiness)

    group 5: respiratory (including dyspnea, cough, or pharyngitis)

    The most common and uncommon side effects associated with Abamune-L® are::

    • skin rash
    • nausea
    • vomiting
    • diarrhea
    • stomach pain
    • headache
    • cough
    • nasal irritation
    • runny nose
    • fever
    • muscle pain and discomfort
    • joint pain
    • hair loss
    • tiredness
    • loss of appetite
    • insomnia
    Contraindications

    Abamune-L® is contraindicated in patients who are allergic to Abacavir, Lamivudine or any of the other ingredients of Abamune-L®.

    Do not combine Abamune-L® with abacavir-containing, lamivudine-containing and emtricitabine-containing products, interferon alfa with or without ribavirin.

    Abamune-L® is contraindicated in patients who carry the HLA-B*5701 allele because they are at high risk for experiencing allergy to Abacavir. Never restart Abamune-L® or any other abacavir-containing product following allergic reaction to Abacavir, regardless of HLA-B*5701 status.

    Abamune-L® is contraindicated in patients with heart disease, high blood pressure, liver disease, a risk factor for heart disease such as smoking, diabetes, or high cholesterol, or if you have used any other HIV medication in the past.

    Abamune-L® is contraindicated in patients with impaired renal and hepatic function.

    Consult your doctor before taking Abamune-L® if you are pregnant or plan to have a baby.

    Women who are HIV-positive must not breastfeed because HIV infection can be passed on to the baby in breast milk.

  • F.A.Q.

    Abamune-L® is an antiviral agent used as part of anti-retroviral therapy of HIV-1 infection. Abamune-L® doesn't cure HIV-1 infection but it decreases the viral load in blood and enhances CD4 cells production to help ward off opportunistic infections. Abamune-L® is not for use in patients aged less than 18 years.

    Other names for this medication:

    Abalam®, A Bec L®, Epzicom, Kivexa®

    Similar Products:

    A Bec®, Virol®, Ziagen, Abamune®, Lamivir®, Lamivir® HBV, Epivir HBV, Tenvir®, Viread, Zidovir®, Efavir®, Stocrin, Nevimune®, Viramune, Atazor®, Reyataz, Daruvir®, Prezista, Ritomune®, Norvir, Isentress®, Zepdon®

    Active Ingredient:

    Abacavir, Lamivudine

    Q: What is Abamune-L® used for?

    A:Abamune-L® is an antiviral agent used as part of anti-retroviral therapy of HIV-1 infection.

    Q:Is Abamune-L® safe

    A:Abamune-L® is safe if taken as prescribed by your doctor.

    Q: Is Abamune-L® safe during pregnancy

    A: Consult your doctor before taking Abamune-L® if you are pregnant or plan to have a baby.

  • Shipping Options

    Registered Mail  USD 20.00

    Registered Mail (14-21 business days). No online tracking is available.

    EMS  USD 30.00

    EMS (5-9 business days). Online tracking is available!

  • Testimonials

Leave Your Comment